Pacific Biosciences of California Inc [NASDAQ: PACB] traded at a low on 11/08/23, posting a -2.76 loss after which it closed the day’ session at $6.69. The company report on November 2, 2023 at 9:05 AM that PacBio Announces HiFi Solves, a Global Consortium of Clinical Genomics Research Leaders.
Consortium Aims to Share Best Practices and Increase our Understanding of Genetic Disease.
PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the creation of the HiFi Solves consortium. This global consortium brings together researchers from 15 leading genomics research institutions across 11 countries to study the value HiFi-based human genome sequencing may have in clinical research applications and to further our understanding of genetic diseases. These institutions will collaborate to develop and share best practices on data generated from PacBio Revio sequencing systems, with the goal of leveraging the comprehensiveness and completeness of HiFi genomes in human genetics research applications.
The results of the trading session contributed to over 4507366 shares changing hands. Over the past one week, the price volatility of Pacific Biosciences of California Inc stands at 7.06% while the volatility over the past one month is 6.95%.
The market cap for PACB stock reached $1.68 billion, with 250.56 million shares outstanding and 242.13 million shares in the current float. Compared to the average trading volume of 4.37M shares, PACB reached a trading volume of 4507366 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Pacific Biosciences of California Inc [PACB]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for PACB shares is $12.25 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on PACB stock is a recommendation set at 1.75. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Cantor Fitzgerald have made an estimate for Pacific Biosciences of California Inc shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on October 31, 2023.
The Average True Range (ATR) for Pacific Biosciences of California Inc is set at 0.54, with the Price to Sales ratio for PACB stock in the period of the last 12 months amounting to 9.89. The Price to Book ratio for the last quarter was 2.26, with the Price to Cash per share for the same quarter was set at 3.07.
How has PACB stock performed recently?
Pacific Biosciences of California Inc [PACB] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 12.06. With this latest performance, PACB shares dropped by -25.91% in over the last four-week period, additionally sinking by -43.83% over the last 6 months – not to mention a drop of -20.55% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for PACB stock in for the last two-week period is set at 39.95, with the RSI for the last a single of trading hit 42.05, and the three-weeks RSI is set at 38.82 for Pacific Biosciences of California Inc [PACB]. The present Moving Average for the last 50 days of trading for this stock 8.61, while it was recorded at 6.82 for the last single week of trading, and 10.74 for the last 200 days.
Pacific Biosciences of California Inc [PACB]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Pacific Biosciences of California Inc [PACB] shares currently have an operating margin of -237.58 and a Gross Margin at +38.08. Pacific Biosciences of California Inc’s Net Margin is presently recorded at -244.92.
Return on Total Capital for PACB is now -18.70, given the latest momentum, and Return on Invested Capital for the company is -19.40. Return on Equity for this stock declined to -46.42, with Return on Assets sitting at -16.65. When it comes to the capital structure of this company, Pacific Biosciences of California Inc [PACB] has a Total Debt to Total Equity ratio set at 168.59. Additionally, PACB Total Debt to Total Capital is recorded at 62.77, with Total Debt to Total Assets ending up at 53.70. Long-Term Debt to Equity for the company is recorded at 166.68, with the Long-Term Debt to Total Capital now at 62.06.
Reflecting on the efficiency of the workforce at the company, Pacific Biosciences of California Inc [PACB] managed to generate an average of -$408,645 per employee. Receivables Turnover for the company is 5.96 with a Total Asset Turnover recorded at a value of 0.07.Pacific Biosciences of California Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 4.43 and a Current Ratio set at 4.80.
Earnings analysis for Pacific Biosciences of California Inc [PACB]
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for PACB. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Pacific Biosciences of California Inc go to -1.00%.
Insider trade positions for Pacific Biosciences of California Inc [PACB]
The top three institutional holders of PACB stocks are: VANGUARD GROUP INC with ownership of 1.3 billion shares, which is approximately 8.2579%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $201.66 billion in PACB stocks shares; and BERKSHIRE HATHAWAY INC, currently with $177.59 billion in PACB stock with ownership which is approximately 5.7994%.